Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 111
- Registration Number
- NCT00722293
- Locations
- 🇨🇭
GSK Investigational Site, St Gallen, Switzerland
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT00719550
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 46
- Registration Number
- NCT00705315
- Locations
- 🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷State General Hospital of Larissa, Dep of Medical Oncology, Larissa,, Greece
🇬🇷"Marika Iliadis" Hospital of Athens, Dep of Medical Oncology, Athens, Greece
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3509
- Registration Number
- NCT00625898
- Locations
- 🇺🇸
Peninsula Regional Oncology & Hematology, Salisbury, Maryland, United States
🇺🇸Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸The Office of Frederik Smith, Chevy Chase, Maryland, United States
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 489
- Registration Number
- NCT00615602
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2007-11-09
- Target Recruit Count
- 94
- Registration Number
- NCT00556127
- Locations
- 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹Ospedale S. Gerardo, Monza, Italy
🇮🇹Osp. maggiore della Carità, Novara, Italy
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 139
- Registration Number
- NCT00540800
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
🇮🇹Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
🇮🇹Ospedale S. Luca ASL SA 3, Vallo della Lucania, Italy
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2009-02-18
- Lead Sponsor
- Catholic University, Italy
- Target Recruit Count
- 80
- Registration Number
- NCT00531973
- Locations
- 🇮🇹
Catholic University, Rome, RM, Italy
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT00499603
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 105
- Registration Number
- NCT00464646
- Locations
- 🇺🇸
CCOP, Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University Hospital and Medical Center - SUNY, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.